# New clinical trials in Peru: 76 since Nov 2024

Updated October 5, 2026.

76 clinical studies with a site in Peru were first posted on ClinicalTrials.gov from November 12, 2024 to October 5, 2026; 40 have an industry sponsor and 54 are recruiting or about to. The newest, NCT07858968, was posted on October 5, 2026: Pelvic Floor Rehabilitation Programme for Women With Urinary Incontinence in a Peruvian Public Hospital (Hospital Nacional Edgardo Rebagliati Martins).

## The full list

New clinical trials with a site in Peru: 76 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/country/peru

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 76
- Industry sponsored: 40
- Recruiting or not yet: 54
- Latest posted: October 5, 2026

## Newest trials

The newest 76 of 76, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07858968 | Pelvic Floor Rehabilitation Programme for Women With Urinary Incontinence in a Peruvian Public Hospital | Hospital Nacional Edgardo Rebagliati Martins | Not applicable | Active not recruiting | Urinary Incontinence, Urinary Incontinence, Stress, Urinary Incontinence, Urge, Mixed Urinary Incontinence | 89 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858968) |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 14, 2026 | NCT07818824 | A Clinical Study of the HCMV-TB Vaccine Candidate VIR-1778 in Healthy Adults | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | Tuberculosis | 116 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818824) |
| September 10, 2026 | NCT07813286 | Gamified Web-Based Mindfulness for University Student Stress | Universidad Peruana Cayetano Heredia | Not applicable | Completed | Stress | 20 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813286) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| August 4, 2026 | NCT07744477 | Validation of Serum Metabolite Differences in Patients With Gallstones and Gallbladder Cancer | Centre Paul Strauss | Observational | Completed | Gallstone Disease, Gallbladder Malignant Neoplasm | 230 | Bolivia, Chile, Germany, Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744477) |
| June 25, 2026 | NCT07667738 | Evaluating the Effectiveness of the Common Elements Treatment Approach (CETA) in Peru: Mechanisms of Individual and Intergenerational Change | University of Notre Dame | Phase 2 | Recruiting | Violence, Parenting, Poverty, Depression, Mental Health, Posttraumatic Stress, Economic Factors, Child Psychology | 600 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667738) |
| June 22, 2026 | NCT07658976 | Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy | HIV Prevention Trials Network | Phase 3 | Not yet recruiting | HIV Infection, Sexually Transmitted Infection | 400 | Argentina, Brazil, Peru, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658976) |
| June 18, 2026 | NCT07656012 | Re-evaluating the Duration in Children of TB Treatment | University of Wisconsin, Madison | Phase 2 | Not yet recruiting | Tuberculosis | 230 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656012) |
| June 15, 2026 | NCT07647419 | Effect of Aromatherapy and Music Therapy on Physiological Response and Pain During Mandibular Third Molar Extraction | Universidad Científica del Sur | Not applicable | Completed | Dental Anxiety, Third Molar Extraction Surgery | 102 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647419) |
| June 11, 2026 | NCT07643597 | Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients | Hospital Las Higueras | Observational | Recruiting | Acute Kidney Injury, Fluid Overload, Fluid Overload in Dialysis Patients, Critical Illness, Renal Replacement Therapy... | 128 | Brazil, Chile, Colombia, Ecuador, Italy, Mexico, Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643597) |
| June 11, 2026 | NCT07642817 | Validation of Differential Serum Levels for Five Minerals in South American Gallstone Patients With and Without Gallbladder Cancer | Centre Paul Strauss | Observational | Completed | Gallbladder Malignant Neoplasm | 230 | Bolivia, Chile, Germany, Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642817) |
| June 9, 2026 | NCT07635745 | Validation of the Association Between the Abundance of Three Bacterial Genera in Stool Samples and the Risk of Gallbladder Cancer in South... | Centre Paul Strauss | Observational | Completed | Gallbladder Malignant Neoplasm | 120 | Bolivia, Chile, Germany, Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635745) |
| June 5, 2026 | NCT07630714 | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to \< 18 Years... | AstraZeneca | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 24 | Australia, Belgium, Chile, Israel, Japan, Netherlands, Peru, Philippines... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630714) |
| June 3, 2026 | NCT07624305 | A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) | AstraZeneca | Phase 3 | Recruiting | Renal Insufficiency, Chronic | 2,800 | Argentina, Austria, Brazil, Bulgaria, Canada, China, France, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624305) |
| May 28, 2026 | NCT07612332 | Non-Immersive Virtual Reality for Gait and Balance Training in Children With Cerebral Palsy | Universidad Nacional de San Agustin de Arequipa | Not applicable | Not yet recruiting | Cerebral Palsy (CP) | 10 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612332) |
| May 19, 2026 | NCT07595042 | A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Not yet recruiting | Tuberculosis | 900 | Argentina, Australia, Botswana, Brazil, Haiti, India, Kenya, Malawi, Mexico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595042) |
| May 6, 2026 | NCT07569029 | A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | HIV | 42 | Argentina, Peru, United States, Zimbabwe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569029) |
| April 24, 2026 | NCT07549776 | Ultrasound-guided Versus Landmark-based Spinal Anesthesia in Obese Parturients Undergoing Cesarean Section | Instituto Nacional Materno Perinatal, Peru | Not applicable | Completed | Obesity, Cesarean Section | 100 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549776) |
| April 21, 2026 | NCT07543458 | Therapeutics for Moderate and Severe Dengue | Oxford University Clinical Research Unit, Vietnam | Phase 3 | Not yet recruiting | Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA... | 8,800 | Bangladesh, Brazil, Colombia, Indonesia, Malaysia, Nepal, Peru, Philippines... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543458) |
| March 17, 2026 | NCT07477041 | Promotion of Breast Milk Donation in Breastfeeding Mothers Through a Mobile Health Intervention Using Amamantapp | National University of San Marcos, Peru | Not applicable | Completed | Health Knowledge Attitudes and Practice, Breast Feeding | 112 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477041) |
| March 2, 2026 | NCT07441408 | Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Pulmonary Fibrosis | 2,380 | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441408) |
| February 24, 2026 | NCT07430592 | This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the... | R. Kiplin Guy | Phase 2 | Not yet recruiting | Malaria, Malaria Vivax, Radical Cure | 104 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430592) |
| February 5, 2026 | NCT07390955 | A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | HIV | 83 | Peru, United States, Zimbabwe | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390955) |
| January 23, 2026 | NCT07363590 | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) | Merck Sharp & Dohme LLC | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 21 | Australia, Belgium, China, Colombia, Georgia, Italy, Japan, Moldova, Peru... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07363590) |
| January 23, 2026 | NCT07361510 | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung... | Bristol-Myers Squibb | Phase 3 | Recruiting | Non-Small Cell Lung Cancer (NSCLC) | 750 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361510) |
| January 6, 2026 | NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Neoplasms, Ovarian Cancer | 900 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318558) |
| December 16, 2025 | NCT07284459 | Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Contineum Therapeutics | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 324 | Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284459) |
| December 3, 2025 | NCT07262320 | Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America | University of Alabama at Birmingham | Observational | Recruiting | Dialysis, Critically Ill Acute Kidney Injury, Renal Replacement Therapy for Acute Kidney Injury in ICU, Acute Kidney... | 1,000 | Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262320) |
| October 28, 2025 | NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated... | mAbxience Research S.L. | Phase 3 | Recruiting | Advanced (Unresectable or Metastatic) Melanoma | 632 | Bosnia and Herzegovina, Brazil, Chile, Georgia, Greece, Italy, Peru, Portugal... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221734) |
| October 7, 2025 | NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | 532 | China, Georgia, India, Indonesia, Japan, Moldova, Peru, Philippines, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209761) |
| September 26, 2025 | NCT07193771 | Altitude and Outcomes in Pediatric ARDS: A Multicenter Study | Latin American Pediatric Collaborative Network | Observational | Recruiting | Respiratory Distress Syndrome, Pediatric, Altitude Hypoxia, High Altitude Effects | 1,600 | Bolivia, Chile, Colombia, Peru, Uruguay | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193771) |
| September 25, 2025 | NCT07192991 | Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America | Latin American Cooperative Oncology Group | Observational | Recruiting | Neuroendocrine Carcinomas, Lung Neuroendocrine Carcinoma | 200 | Argentina, Brazil, Mexico, Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07192991) |
| September 24, 2025 | NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 675 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190248) |
| September 10, 2025 | NCT07165496 | Text Messaging to Promote HIV Testing in Gay Men | Universidad Peruana Cayetano Heredia | Not applicable | Completed | HIV Testing | 400 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07165496) |
| August 17, 2025 | NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor... | Taiho Oncology, Inc. | Phase 3 | Recruiting | Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early... | 360 | Argentina, Australia, Belgium, Brazil, Canada, France, Germany, Greece, Hong... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128199) |
| July 28, 2025 | NCT07088926 | A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis... | AstraZeneca | Phase 2 | Recruiting | Bronchiectasis With Pseudomonas Aeruginosa Colonization | 435 | Argentina, Australia, Belgium, Brazil, Canada, Chile, Denmark, France, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07088926) |
| July 24, 2025 | NCT07082738 | A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | AstraZeneca | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 987 | Argentina, Australia, Bulgaria, Canada, Chile, China, Denmark, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082738) |
| July 20, 2025 | NCT07074899 | Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru | Fred Hutchinson Cancer Center | Not applicable | Completed | HIV/AIDS, Mobile Health, Feasibility Studies, Qualitative Research, Implementation Science, Social Determinants of... | 161 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07074899) |
| July 16, 2025 | NCT07069400 | An International Observational Study of Adults With Acute Infection | University of Minnesota | Observational | Recruiting | Infectious Disease | 1,500 | Argentina, Australia, Brazil, Côte d’Ivoire, Denmark, France, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07069400) |
| July 11, 2025 | NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Breast Neoplasms | 1,000 | Argentina, Australia, Brazil, Canada, Chile, China, Colombia, France, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07060807) |
| July 8, 2025 | NCT07053839 | Effect of a Daily Text Reminder on Asthma Medication Use, Symptom Control, and Lung Function in Children | ROXANA AZNARAN TORRES | Not applicable | Completed | Asthma in Children | 64 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053839) |
| July 8, 2025 | NCT07053514 | Same-Day Antiretroviral Therapy as a Behavioral Design Intervention to Reduce Stigma in Key Affected Populations | Yale University | Not applicable | Not yet recruiting | Hiv | 139 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053514) |
| June 29, 2025 | NCT07044297 | A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | Merck Sharp & Dohme LLC | Phase 3 | Active not recruiting | Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | 4,390 | Argentina, Brazil, Chile, Colombia, Dominican Republic, France, Guatemala... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044297) |
| June 29, 2025 | NCT07044128 | Validate the Efficacy and the Safety of the Keikku Electronic Stethoscope for Its Indication and Intended Purpose, Under the Intended... | Lapsi Health Holding B.V. | Observational | Recruiting | Heart Murmurs, Wheezing | 149 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044128) |
| June 24, 2025 | NCT07032662 | Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Immunovant Sciences GmbH | Phase 2 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 162 | Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07032662) |
| June 5, 2025 | NCT07006584 | Gait Reeducation Program in Older Adults | Universidad Europea de Madrid | Not applicable | Completed | Older Adults (65 Years and Older), Balance, Gait Disorders, Physical Performance, Calf Muscle Weakness, Abdominal... | 47 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07006584) |
| June 2, 2025 | NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | AstraZeneca | Phase 3 | Recruiting | Cardiovascular Disease | 15,100 | Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07000357) |
| May 30, 2025 | NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | AstraZeneca | Phase 1/2 | Recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 152 | Belgium, Brazil, China, France, Georgia, Germany, Italy, Japan, Malaysia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06996782) |
| May 25, 2025 | NCT06989502 | Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries | Universidad Peruana Cayetano Heredia | Not applicable | Not yet recruiting | Hypertension, Diabetes Mellitus, Neglected Tropical Diseases | 2,094 | Mozambique, Nepal, Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06989502) |
| May 23, 2025 | NCT06987318 | A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | HIV-1-infection | 40 | Brazil, Peru, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987318) |
| May 20, 2025 | NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Malignant Neoplasm | 250 | Argentina, Brazil, Canada, Chile, Malaysia, Peru, Singapore, Spain, Taiwan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06979596) |
| May 20, 2025 | NCT06979531 | Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity | Immunovant Sciences GmbH | Phase 2 | Active not recruiting | Primary Sjögren's Syndrome | 180 | Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Peru, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06979531) |
| May 13, 2025 | NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms | 2,400 | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966700) |
| May 1, 2025 | NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA... | AstraZeneca | Phase 3 | Recruiting | Prostate Cancer | 700 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Finland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952803) |
| May 1, 2025 | NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Endometrial Cancer | 1,123 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952504) |
| April 29, 2025 | NCT06948110 | Deciphering the Genetic Architecture of Autoimmune Diseases | National Human Genome Research Institute (NHGRI) | Observational | Recruiting | Autoimmune Diseases | 300 | Peru, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948110) |
| April 18, 2025 | NCT06934135 | Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder | NeuroThera DE | Not applicable | Completed | Depression, Depressive Disorder, Depressive Disorder, Major | 50 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06934135) |
| April 17, 2025 | NCT06932263 | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled... | AstraZeneca | Phase 2 | Recruiting | Asthma | 540 | Argentina, Brazil, Chile, China, France, Greece, Hungary, India, Israel, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06932263) |
| April 13, 2025 | NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Prostate Cancer, Prostatic Neoplasms | 1,440 | Argentina, Australia, Austria, Brazil, Chile, China, Colombia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925737) |
| March 14, 2025 | NCT06878261 | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | AstraZeneca | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 990 | Argentina, Australia, Belgium, Bulgaria, Colombia, Denmark, France, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06878261) |
| March 4, 2025 | NCT06857461 | Effect of the Uriclarity Program on Perceived Milk Supply in Postpartum Women in Piura-Peru | Crianzamor | Not applicable | Completed | Perceived Insufficient Milk Supply | 91 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06857461) |
| February 24, 2025 | NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Triple Negative Breast Neoplasms | 1,000 | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841354) |
| February 18, 2025 | NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ | 308 | Argentina, Australia, Brazil, Canada, Chile, Colombia, Denmark, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06833073) |
| February 13, 2025 | NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 770 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06824467) |
| February 6, 2025 | NCT06812494 | A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Active not recruiting | HIV | 200 | Brazil, Peru, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06812494) |
| January 15, 2025 | NCT06777407 | Brief Mindfulness-Based Intervention to Reduce Psychological Distress in Health Sciences Students | National University of San Marcos, Peru | Not applicable | Unknown | Mindfulness, Psychological Distress | 120 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06777407) |
| January 9, 2025 | NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for... | AstraZeneca | Phase 3 | Recruiting | HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 840 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06764875) |
| December 27, 2024 | NCT06751186 | Effect of Teté Dance on Breastfeeding Duration in Irritable Infants | Crianzamor | Not applicable | Completed | Breastfeeding Duration, Infant Feeding Practices | 150 | Peru | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751186) |
| December 24, 2024 | NCT06747949 | A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Amgen | Phase 3 | Recruiting | Sjögren's Syndrome | 844 | Argentina, Australia, Belgium, Brazil, Canada, Chile, Croatia, France, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06747949) |
| December 19, 2024 | NCT06742723 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With... | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease and Hypertension | 5,000 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06742723) |
| December 5, 2024 | NCT06717347 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP)... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Diffuse Large B-Cell Lymphoma | 1,046 | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06717347) |
| November 26, 2024 | NCT06705478 | Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in... | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Suspended | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 186 | Botswana, Brazil, India, Kenya, Malawi, Mexico, Peru, Philippines, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06705478) |
| November 20, 2024 | NCT06698042 | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer... | Merck Sharp & Dohme LLC | Phase 3 | Active not recruiting | Lung Cancer, Non-Small Cell Lung Cancer | 67 | China, Germany, Guatemala, Japan, Peru, Poland, Romania, South Korea, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06698042) |
| November 18, 2024 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic... | AstraZeneca | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 1,160 | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06692738) |
| November 12, 2024 | NCT06684847 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | argenx | Phase 3 | Active not recruiting | Primary Sjogrens Disease | 631 | Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06684847) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| AstraZeneca | 14 | October 1, 2026 |
| Merck Sharp & Dohme LLC | 14 | January 23, 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 7 | September 14, 2026 |
| Universidad Peruana Cayetano Heredia | 3 | September 10, 2026 |
| Centre Paul Strauss | 3 | August 4, 2026 |
| National University of San Marcos, Peru | 2 | March 17, 2026 |
| Bristol-Myers Squibb | 2 | March 2, 2026 |
| Immunovant Sciences GmbH | 2 | June 24, 2025 |
| Crianzamor | 2 | March 4, 2025 |
| Hospital Nacional Edgardo Rebagliati Martins | 1 | October 5, 2026 |
| University of Notre Dame | 1 | June 25, 2026 |
| HIV Prevention Trials Network | 1 | June 22, 2026 |
| University of Wisconsin, Madison | 1 | June 18, 2026 |
| Universidad Científica del Sur | 1 | June 15, 2026 |
| Hospital Las Higueras | 1 | June 11, 2026 |
| Universidad Nacional de San Agustin de Arequipa | 1 | May 28, 2026 |
| Instituto Nacional Materno Perinatal, Peru | 1 | April 24, 2026 |
| Oxford University Clinical Research Unit, Vietnam | 1 | April 21, 2026 |
| R. Kiplin Guy | 1 | February 24, 2026 |
| Contineum Therapeutics | 1 | December 16, 2025 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 6 | January 23, 2026 |
| [Acquired Immunodeficiency Syndrome](https://specstream.ai/data/clinical-trials/condition/acquired-immunodeficiency-syndrome) | 4 | June 22, 2026 |
| Tuberculosis | 3 | September 14, 2026 |
| [Renal Insufficiency, Chronic](https://specstream.ai/data/clinical-trials/condition/renal-insufficiency-chronic) | 3 | August 10, 2026 |
| Gallbladder Neoplasms | 3 | August 4, 2026 |
| [Lupus Erythematosus, Systemic](https://specstream.ai/data/clinical-trials/condition/lupus-erythematosus-systemic) | 3 | June 5, 2026 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 3 | May 13, 2025 |
| Fallopian Tube Neoplasms | 2 | October 1, 2026 |
| [Depression](https://specstream.ai/data/clinical-trials/condition/depression) | 2 | June 25, 2026 |
| [Psychological Well-Being](https://specstream.ai/data/clinical-trials/condition/psychological-well-being) | 2 | June 25, 2026 |
| [HIV Infections](https://specstream.ai/data/clinical-trials/condition/hiv-infections) | 2 | June 22, 2026 |
| [Acute Kidney Injury](https://specstream.ai/data/clinical-trials/condition/acute-kidney-injury) | 2 | June 11, 2026 |
| [Breast Feeding](https://specstream.ai/data/clinical-trials/condition/breast-feeding) | 2 | March 17, 2026 |
| Pulmonary Fibrosis | 2 | March 2, 2026 |
| Idiopathic Pulmonary Fibrosis | 2 | March 2, 2026 |
| [Ovarian Neoplasms](https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms) | 2 | January 6, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 2 | August 17, 2025 |
| [Pulmonary Disease, Chronic Obstructive](https://specstream.ai/data/clinical-trials/condition/pulmonary-disease-chronic-obstructive) | 2 | July 24, 2025 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 2 | July 11, 2025 |
| [Asthma](https://specstream.ai/data/clinical-trials/condition/asthma) | 2 | July 8, 2025 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 2 | May 25, 2025 |
| [Triple Negative Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/triple-negative-breast-neoplasms) | 2 | May 13, 2025 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 2 | May 1, 2025 |
| [Depressive Disorder, Major](https://specstream.ai/data/clinical-trials/condition/depressive-disorder-major) | 2 | April 18, 2025 |
| [Urinary Incontinence](https://specstream.ai/data/clinical-trials/condition/urinary-incontinence) | 1 | October 5, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 29 | October 1, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 16 | October 5, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 15 | June 25, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 10 | August 4, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 5 | September 14, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 1 | May 30, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).